These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28435454)

  • 21. Guideline for PET/CT imaging of neuroendocrine neoplasms with
    Bozkurt MF; Virgolini I; Balogova S; Beheshti M; Rubello D; Decristoforo C; Ambrosini V; Kjaer A; Delgado-Bolton R; Kunikowska J; Oyen WJG; Chiti A; Giammarile F; Sundin A; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1588-1601. PubMed ID: 28547177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use and perceived utility of [
    Ambrosini V; Caplin M; Castaño JP; Christ E; Denecke T; Deroose CM; Dromain C; Falconi M; Grozinsky-Glasberg S; Hicks RJ; Hofland J; Kjaer A; Knigge UP; Kos-Kudla B; Koumarianou A; Krishna B; Lamarca A; Pavel M; Reed NS; Scarpa A; Srirajaskanthan R; Sundin A; Toumpanakis C; Prasad V
    J Neuroendocrinol; 2024 Jan; 36(1):e13359. PubMed ID: 38097193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
    Zalom ML; Waxman AD; Yu R; Lee J; Ih G; Wolin EM
    Endocr Pract; 2009; 15(6):521-7. PubMed ID: 19491080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Positron emission tomography in neuroendocrine tumours].
    Biermann M; Johnsen B; Sørbye H; Følling M; Sundin A; Bach-Gansmo T
    Tidsskr Nor Laegeforen; 2009 Aug; 129(15):1474-7. PubMed ID: 19690598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating Prognosis of Gastrointestinal Metastatic Neuroendocrine Tumors: Constructing a Novel Prognostic Nomogram Based on NETPET Score and Metabolic Parameters from PET/CT Imaging.
    Liu Y; Cui R; Wang Z; Lin Q; Tang W; Zhang B; Li G; Wang Z
    Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
    Abdulrezzak U; Kurt YK; Kula M; Tutus A
    Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors.
    Garin E; Le Jeune F; Devillers A; Cuggia M; de Lajarte-Thirouard AS; Bouriel C; Boucher E; Raoul JL
    J Nucl Med; 2009 Jun; 50(6):858-64. PubMed ID: 19443590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management.
    Kunikowska J; Lewington V; Krolicki L
    Clin Nucl Med; 2017 Dec; 42(12):905-911. PubMed ID: 29076910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours.
    Hofman MS; Kong G; Neels OC; Eu P; Hong E; Hicks RJ
    J Med Imaging Radiat Oncol; 2012 Feb; 56(1):40-7. PubMed ID: 22339744
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
    J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
    Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
    Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the Diagnosis of Neuroendocrine Neoplasms.
    Kulkarni HR; Singh A; Baum RP
    Semin Nucl Med; 2016 Sep; 46(5):395-404. PubMed ID: 27553465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of
    Bongiovanni A; Recine F; Riva N; Foca F; Liverani C; Mercatali L; Nicolini S; Pieri F; Amadori D; Ibrahim T
    Clin Lung Cancer; 2017 Jul; 18(4):415-420. PubMed ID: 27956089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of early dynamic and delayed post-diuretic
    Sharma A; Mete UK; Sood A; Kakkar N; Gorla AK; Mittal BR
    Br J Radiol; 2017 Apr; 90(1072):20160787. PubMed ID: 28256904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at
    Ruuska T; Ramírez Escalante Y; Vaittinen S; Gardberg M; Kiviniemi A; Marjamäki P; Kemppainen J; Jyrkkiö S; Minn H
    Acta Oncol; 2018 Feb; 57(2):283-289. PubMed ID: 28686510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
    Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
    Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.